Roivant Sciences Business Segments — Net (loss) income decreased by 88.9% to -$313.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 365.7%, from $118.08M to -$313.70M. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher net income indicates strong operational performance and commercial success, while net losses may indicate high R&D investment or underperforming commercial assets.
This represents the bottom-line financial performance of a specific reportable segment after all operating expenses, int...
Comparable to segment operating profit or segment net income reported by other biopharmaceutical companies with multiple business lines.
roiv_segment_reportable_segment_net_loss_income| Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $1.06B | $1.06B | $1.06B | $1.06B | -$279.92M | $118.08M | -$252.38M | -$166.04M | -$313.70M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -126.5% | +142.2% | -313.7% | +34.2% | -88.9% |
| YoY Change | — | — | — | — | -126.5% | -88.8% | -123.9% | +40.7% | -365.7% |